ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NVAX Novavax Inc

4.90
0.19 (4.03%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Novavax Inc NASDAQ:NVAX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.19 4.03% 4.90 4.77 5.00 4.94 4.6895 4.84 4,668,267 05:00:08

Novavax to Present at the 14th Annual Needham Healthcare Conference

08/04/2015 9:01pm

GlobeNewswire Inc.


Novavax (NASDAQ:NVAX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Novavax Charts.

Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Stanley C. Erck, President and Chief Executive Officer, will present at the 14th Annual Needham Healthcare Conference at 8:00 a.m. ET, April 15, 2015 in New York City at the Westin Grand Central Hotel.

A live webcast link for the presentation will be available via the company website at www.novavax.com under Investor Info/Events.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website, www.novavax.com.

CONTACT: Novavax, Inc.
         
         Barclay A. Phillips
         SVP, Chief Financial Officer and Treasurer
         
         Andrea N. Flynn, Ph.D.
         Senior Manager, Investor Relations
         
         ir@novavax.com
         240-268-2000
         
         Russo Partners, LLC
         
         David Schull
         Todd Davenport, Ph.D.
         
         david.schull@russopartnersllc.com
         todd.davenport@russopartnersllc.com
         212-845-4271

1 Year Novavax Chart

1 Year Novavax Chart

1 Month Novavax Chart

1 Month Novavax Chart

Your Recent History

Delayed Upgrade Clock